HLS Therapeutics (HLS) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Strategic changes and leadership

• Significant leadership changes at board and senior management levels over the past year and a half.

• Shifted focus from a mixed product/royalty model to prioritizing the product portfolio.

• Streamlined operations, reduced operating expenses, and divested non-strategic assets.

• Strengthened the balance sheet by deleveraging and rationalizing the portfolio.

• Immediate focus on integrating new leadership and resetting the business for growth.

Product portfolio and market position

• Operates as a commercial-stage, revenue-generating company with positive adjusted EBITDA.

• Core focus on cardiovascular and psychiatric disorders, with strong Canadian market capabilities.

• Clozaril, for treatment-resistant schizophrenia, maintains leading market share in Canada and stable revenues.

• Vascepa, for cardiovascular risk, shows strong growth potential and is protected by patents until 2039 in Canada.

• Both products have demonstrated consistent patient and revenue growth.

Innovation and competitive advantage

• Developed a best-in-class patient support network and unique technology (CSAN Pronto) for Clozaril.

• CSAN Pronto enables point-of-care blood monitoring, improving compliance by 30% over competitors.

• Eight consecutive years of patient growth for Clozaril, with opportunities for further market share gains.

• Vascepa supported by robust clinical data (REDUCE-IT, EVAPORATE) and strong medical society endorsements.

• Recent expansion of Vascepa coverage to major Canadian provinces and transition of promotion in-house for cost savings.